Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

1044 results about "Lactobacillus rhamnosus" patented technology

Lactobacillus rhamnosus is a bacterium that originally was considered to be a subspecies of L. casei, but genetic research found it to be a species of its own. It is a short Gram-positive heterofermentative facultative anaerobic non-spore-forming rod that often appears in chains. Some strains of L. rhamnosus bacteria are being used as probiotics, and are particularly useful in treating female-related infections, most particularly very difficult to treat cases of bacterial vaginosis (or "BV"). The Lactobacillus rhamnosus and L. reuteri species are most commonly found in the healthy female genito-urinary tract and are most helpful to supplement in order to regain control over dysbiotic bacterial overgrowth during an active infection. L. rhamnosus sometimes is used in yogurt and dairy products such as fermented and unpasteurized milk and semi-hard cheese. While frequently considered a beneficial organism, L. rhamnosus may not be as beneficial to certain subsets of the population; in rare circumstances, especially those primarily involving weakened immune system or infants, it may cause endocarditis.

Five-union bacteria for conditioning and improving diarrhea, constipation and irritable bowel syndrome

The invention discloses a quintuple bacterium for conditioning and improving diarrhea, constipation and irritable bowel syndrome. The quintuple bacteria comprise lactobacillus reuteri HBM11-69, pediococcus pentosaceus MPL5, lactobacillus plantarum La-10, lactobacillus rhamnosus HBM11-35 and lactobacillus casei C7-2 bacteria, and the lactobacillus rhamnosus HBM11-35, the pediococcus pentosaceus MPL5, the lactobacillus plantarum La-10, the lactobacillus rhamnosus HBM11-35 and the lactobacillus The strain is found by a Lin Junjunch Teaching Team of South China Agricultural University. The probiotic composition disclosed by the invention is mutually matched and has a synergistic effect, and the intestinal flora structure balance can be effectively recovered by improving the small intestine propulsion rate, reducing the diarrhea frequency and the like. No matter in a viable or inactivated state, the traditional Chinese medicine composition has a relatively good improvement effect on gastrointestinal discomfort such as constipation and irritable bowel syndrome. The quintuplet compound probiotics are high in safety, do not cause adverse reactions such as electrolyte imbalance and can be used for preparing medicines or health foods or foods.
Owner:JIANMA PHARM (GUANGDONG) CO LTD

High-activity lactobacillus rhamnosus probiotic microcapsule and application thereof

The invention relates to the technical field of biological medicines, and discloses a high-activity lactobacillus rhamnosus probiotic microcapsule, which comprises the following components in parts by weight: lactobacillus rhamnosus: each gram of formula contains 1010 CFU; bifidobacterium: each gram of the formula contains 109 CFU; 10% to 20% of sodium alginate; 5%-15% of chitosan; 3%-8% of hydroxypropyl methyl cellulose; 3%-7% of pectin; 5% to 10% of fructo-oligosaccharide; 5%-10% of inulin; 0.1%-0.5% of vitamin C; and 0.1%-0.3% of vitamin E. Through double-layer and three-layer embedding technologies (such as compound use of sodium alginate and chitosan and compound use of pectin and gelatin), the tolerance of the probiotics in gastric acid and bile environments is remarkably improved, the probiotics are effectively protected through a multi-layer embedding structure, the survival rate of the probiotics in the gastric environment reaches up to 90%, and the release rate in the small intestine exceeds 75%.
Owner:HENAN BUSINESS SCI RES INST

Probiotic microcapsule with function of improving intestinal microecology and key technology

The invention relates to the technical field of biological pharmacy, and discloses a probiotic microcapsule with a function of improving intestinal microecology, which comprises the following components in percentage by weight: lactobacillus rhamnosus: each gram of formula contains 1010 CFU of lactobacillus rhamnosus; lactobacillus acidophilus: each gram of the formula contains 109 CFU; clostridium butyricum: each gram of the formula contains 108 CFU; 5%-8% of a nano sodium alginate-chitosan compound; 3%-5% of peptide nanoparticles; 2%-4% of a natural polymer intelligent response film; 3%-6% of arabinoxylan oligosaccharide; 4%-7% of resistant dextran; 2%-4% of lentinan; and 0.1%-0.3% of resveratrol. Through a double-layer or three-layer embedding technology of the nano sodium alginate-chitosan compound and the intelligent response polymer film, the tolerance of the probiotics in gastric acid and cholate environments is remarkably enhanced, and targeted release of the probiotics in small intestines and colon is ensured.
Owner:HENAN BUSINESS SCI RES INST

Lactobacillus rhamnosus CBBM005 and application of lactobacillus rhamnosus CBBM005 in product for balancing intestinal flora, improving immunity and improving oral cavity

The invention relates to lactobacillus rhamnosus CBBM005 and application thereof in products for balancing intestinal flora, improving immunity and improving oral cavity, and belongs to the technical field of microorganisms. The lactobacillus rhamnosus CBBM005 is separated from human intestinal secretion, the lactobacillus rhamnosus CBBM005 is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation time is March 20, 2025, and the preservation number is CGMCC NO.33904. The lactobacillus rhamnosus CBBM005 has the characteristics of balancing intestinal flora, improving immunity and improving oral cavity.
Owner:JIANGSU LANZE BIOTECHNOLOGY CO LTD

Lactobacillus paracasei JNL0025 and application thereof

The invention belongs to the technical field of microorganisms, and relates to a lactobacillus paracasei JNL0025 strain and application thereof. Compared with a commercial strain lactobacillus casei substitute strain, the lactobacillus paracasei JNL0025 provided by the invention has the advantages that the guanine nucleoside conversion rate is improved, the inhibition rate of supernate on XOD is equivalent, and the inhibition on PNP activity can be realized; according to the lactobacillus paracasei JNL0025 disclosed by the invention, the lactobacillus paracasei JNL0025 has the effects of reducing the tendency of pro-inflammatory M1 type macrophages, increasing the proportion of anti-inflammatory M2 type macrophages and inhibiting secretion of pro-inflammatory cytokines TNF-alpha and IL-6, and the lactobacillus paracasei JNL0025 has a better inflammation inhibition effect than the lactobacillus rhamnosus LGG; animal experiment results show that the lactobacillus paracasei JNL0025 provided by the invention can significantly reduce the blood uric acid level of a hyperuricemia model mouse, alleviate the kidney inflammation level and alleviate DSS-induced colitis, and shows a huge application value.
Owner:JINAN MICROECOLOGY & BIOMEDICINE PROVINCIAL LAB

Lactobacillus rhamnosus capable of maintaining bone health and improving local inflammation of joints as well as metagen and application of lactobacillus rhamnosus

The invention belongs to the technical field of microbial fermentation, and particularly relates to lactobacillus rhamnosus capable of maintaining bone health and improving local joint inflammation and a metagen and application of the lactobacillus rhamnosus. According to the invention, the probiotic NKU ML1-2 is subjected to fermentation culture, such that a post-generation product is prepared. Results of embodiments prove that the metagen product can enhance the oxidation resistance of cartilage and osteoblasts and promote the synthesis of anti-inflammatory factors and cartilage matrixes (type II collagen and proteoglycan), and has the potential of relieving oxidative stress and inflammatory response of local joints, relieving joint inflammation and delaying cartilage destruction. The prepared metagen product is high in safety and good in stability, and can be applied to preparation of medicines for preventing and / or treating osteoarthritis; the metagen product can also be used for promoting bone health, enhancing the antioxidant capacity of osteoblasts and / or chondrocytes, promoting osteoblast activity and / or promoting calcium absorption and fixation, and a new solution is provided for joint health management.
Owner:TIANTIANNENG HEALTH IND GRP CO LTD +1

Application of lactobacillus rhamnosus KF7 in improving intestinal barrier injury and regulating intestinal flora and functional food containing lactobacillus rhamnosus KF7

The invention relates to the technical field of microorganisms, in particular to application of lactobacillus rhamnosus KF7 in improving intestinal barrier injury and regulating intestinal flora and functional food containing the lactobacillus rhamnosus KF7. The invention provides application of lactobacillus rhamnosus KF7 in preparation of a product for improving intestinal barrier injury and / or regulating intestinal flora. The preservation number of the lactobacillus rhamnosus KF7 is CGMCC (China General Microbiological Culture Collection Center) NO.6430. The invention further provides application of the lactobacillus rhamnosus KF7 in preparation of a product for improving intestinal barrier injury and / or regulating intestinal flora. The invention discloses the novel application of the caseus rhamnosus KF7 in the aspects of improving the normal intestinal epithelial barrier function, protecting the normal intestinal epithelial barrier from lipopolysaccharide induced barrier injury, recovering animal intestinal barrier injury caused by rhythm disorder, regulating intestinal flora disorder and improving growth, development and metabolic states for the first time. The method can be used for producing functional food products such as fermented milk, lactic acid bacteria beverages, probiotic powder, viable bacteria water, milk powder and cheese.
Owner:BRIGHT DAIRY & FOOD CO LTD

Application of lactobacillus rhamnosus HPT112 in preparation of medicine for preventing and / or treating hyperuricemia

The invention discloses application of lactobacillus rhamnosus HPT112 in preparation of a medicine for preventing and / or treating hyperuricemia, and belongs to the field of microorganisms, the lactobacillus rhamnosus HPT112 is preserved in the China Center for Type Culture Collection on November 20, 2023, and the preservation number is CCTCC NO: M20232273. Tests prove that the lactobacillus rhamnosus HPT112 has the function of regulating bile acid metabolism, so that the uric acid reducing effect is achieved, and the uric acid reducing effect equivalent to or even better than that of an existing hyperuricemia medicine can be achieved. Compared with existing hyperuricemia drugs, the lactobacillus rhamnosus HPT112 has the advantages that toxic and side effects are low, safety is high, a brand-new drug for preventing and / or treating hyperuricemia can be developed by the aid of the lactobacillus rhamnosus HPT112, and accordingly inflammatory reaction caused by hyperuricemia can be prevented and / or treated.
Owner:TONGHUA CHENGCHENG PHARM CO LTD

Lactobacillus rhamnosus GS044, a freeze-dried powder thereof, and a probiotic in promoting growth and development and improving immunity

The application provides a lactobacillus rhamnosus GS044 and a lyophilized powder and a probiotic of the lactobacillus rhamnosus GS044 in application to promoting growth and development and improving immunity, and belongs to the technical field of microorganisms.The application provides a lactobacillus rhamnosus GS044 with a preservation number of CGMCC No.33713.The application further provides a method for preparing gamma-aminobutyric acid by using the lactobacillus rhamnosus GS044, and a lyophilized powder prepared by using the lactobacillus rhamnosus GS044, a probiotic and application of the lyophilized powder and the probiotic.The lyophilized powder and the probiotic prepared by the application can effectively promote growth and development and improve immunity.
Owner:天津芯源生物科技有限公司 +1

Probiotic and traditional Chinese medicine composition for treating insomnia and application

The invention discloses a composition for treating insomnia. Comprising probiotic compounds: lactobacillus plantarum, bifidobacterium lactis, lactobacillus crispatus, lactobacillus acidophilus, lactobacillus rhamnosus, bifidobacterium bifidum, lactobacillus reuteri, lactobacillus casei, lactobacillus bulgaricus, lactobacillus fermentum, lactobacillus gasseri, lactococcus lactis, bifidobacterium longum, lactobacillus salivarius, bifidobacterium breve, streptococcus thermophilus and lactobacillus paracasei; lactobacillus helveticus; and traditional Chinese medicine components and prebiotics. Probiotics are matched with traditional Chinese medicines with homology of medicine and food, and corresponding prebiotics are supplemented, so that the balance of intestinal flora can be adjusted and information transmission between intestines and cranial nerves can be promoted through the synergistic effect of the probiotics and the corresponding prebiotics, and then gastrointestinal inflammation, ulcer, helicobacter pylori infection, constipation and insomnia are treated or improved; and treating or improving spleen and stomach disharmony, liver qi stagnation, excessive heart fire, fire excess from yin deficiency, heart-kidney disharmony caused by emotion, pressure, diseases and the like, and insomnia caused by the symptoms.
Owner:BEIJING BAO YUAN GUANG TONG TECHNOLOGY DEVELOPMENT CO LTD

Compound probiotics for relieving anxiety behavior and application thereof

The invention provides a compound probiotic for relieving anxiety behaviors and application of the compound probiotic. The compound probiotic comprises bifidobacterium animalis YRK-12 (the preservation number is CGMCC (China General Microbiological Culture Collection Center) NO.28597) and lactobacillus rhamnosus LRa-Y8 (the preservation number is CGMCC NO.34186). The invention finds that the two bacteria are compounded and can be matched and promoted with each other, and have a synergistic effect on the aspect of preventing and treating anxiety disorder, which is specifically shown as follows: the reduction of center lattice movement time and percentage caused by LPS (Lipopolysaccharide) is relieved; the increase of mouse serum proinflammatory cytokines caused by LPS is improved; the increase of mouse brain tissue proinflammatory cytokines caused by LPS is improved. Under the condition that the using amount of the bacteria is consistent, the effect of the compounding of the two bacteria on improving the anxiety-like behavior induced by the LPS is obviously improved. Meanwhile, the two bacteria are probiotics, so that the product is safe and is not easy to generate resistance.
Owner:YIRUIKANG BIOTECHNOLOGY (HAINAN) CO LTD +1

Bacteriostatic lactobacillus plantarum with high bacteriocin yield and application thereof

PendingCN119331746AAntibacterial agentsBacteriaBiotechnologyShigella sp
The invention discloses a strain of lactobacillus plantarum, which is named as L.plantarum ZW1, and the preservation number of the lactobacillus plantarum is CGMCC (China General Microbiological Culture Collection Center) 26685. The lactobacillus plantarum provided by the invention is a lactic acid bacterium with relatively strong broad-spectrum inhibition capability, and after the interference of organic acid and hydrogen peroxide is eliminated and protease treatment verification is carried out, the strain is determined to have relatively strong bacteriocin production capability. Probiotic performance evaluation shows that the strain has good digestive tract fluid tolerance, and the L.plantarum CGMCC26685 has good intestinal tract probiotic characteristics, can significantly enrich mouse intestinal flora in an in-vitro intestinal flora fermentation model, increase the relative abundance of the phylum of thick-walled bacteria, reduce the relative abundance of the phylum of proteobacteria, proteusbacillus and shigella, and improve the intestinal tract fluid resistance of mice. The number of flora OTU is obviously higher than that of lactobacillus rhamnosus LGG and lactobacillus plantarum L.plantarum PL4 group which does not produce bacteriocin, and the Chao1 index, the Shannon index and the Simpson index are obviously improved compared with those of a control group. It is shown that the L.plantarum CGMCC26685 has good intestinal tract beneficial activity, and has the potential of further performance excavation and application expansion.
Owner:JIANGNAN UNIV

Probiotic composition for relieving sarcopenia obesity and application thereof

The invention relates to the technical field of biology, and provides a probiotic composition for relieving sarcopenia obesity and application of the probiotic composition. The composition comprises at least two of lactobacillus plantarum, lactobacillus rhamnosus and bifidobacterium animalis subsp. Lactis. Wherein the preservation number of the lactobacillus plantarum is CGMCC (China General Microbiological Culture Collection Center) No.25839; the preservation number of the lactobacillus rhamnosus is CGMCC (China General Microbiological Culture Collection Center) No.26968; the preservation number of the animal bifidobacterium subsp. Lactis is CGMCC (China General Microbiological Culture Collection Center) No. 27998. The composition disclosed by the invention can be used for increasing the muscle content of an organism, improving the muscle tissue form, increasing adenosine triphosphate and inhibiting abnormal increase of body weight, so that the composition can be used for effectively preventing and treating sarcopenia obesity.
Owner:HANGZHOU VICROBX BIOTECH CO LTD

Marine-derived lactobacillus rhamnosus and application thereof

The invention provides marine-derived lactobacillus rhamnosus S400M01 and application thereof, and relates to the technical field of heavy metal adsorption and removal, the marine-derived lactobacillus rhamnosus S400M01 is preserved in Guangdong Microbial Culture Collection Center (GDMCC) on November 28, 2022, the preservation address is Guangzhou, and the number is GDMCCNO: 63001. The strain can tolerate cadmium chloride concentration up to 1000 mg / L, can tolerate lead concentration up to 800 mg / L, can adsorb and remove heavy metals cadmium and lead in squid viscera, and reduces accumulation of cadmium and lead in viscera of live crucian in a heavy metal polluted water body.
Owner:NINGBO XINUOYA MARINE BIOTECH CO LTD

Application of lactobacillus rhamnosus in preparation of preparation for relieving allergic rhinitis

The invention discloses application of lactobacillus rhamnosus in preparation of a preparation for relieving allergic rhinitis. The invention provides application of the lactobacillus rhamnosus OF44-15Ph10T or a composition containing the lactobacillus rhamnosus OF44-15Ph10T in preparation of a product with at least one of the following functions: preventing and / or treating allergic rhinitis; the symptoms of allergic rhinitis are improved or relieved; the nasal mucosa injury caused by allergic rhinitis is repaired; intestinal pathogens are inhibited; the intestinal flora balance is regulated; the lactobacillus rhamnosus OF44-15Ph10T provided by the invention provides a new direction for treating allergic rhinitis, can be applied to the fields of food, health care products and medicines, and has a wide industrial prospect.
Owner:BGI PRECISION NUTRITION (SHENZHEN) TECHNOLOGY CO LTD

Postbiotic hydrogel for relieving alcoholic gastric ulcer as well as preparation method and application thereof

The invention belongs to the technical field of biological medicines, and particularly relates to a postbiotic hydrogel for relieving alcoholic gastric ulcer as well as a preparation method and application thereof. The metagen hydrogel for relieving the alcoholic gastric ulcer, provided by the invention, is mainly prepared from metagen of rhamnobacter and modified lactoferrin; the lactobacillus rhamnosus is lactobacillus rhamnosus JM023. Tests prove that when the postbiotic hydrogel is applied to an alcoholic gastric ulcer rat model, the occurrence of gastric ulcer can be inhibited by inhibiting oxidative stress and inflammatory response and improving protection factor secretion; and the alcoholic gastric ulcer is relieved by regulating and controlling the expression of oxidation, inflammation, cell apoptosis and tissue repair related metabolic pathways and regulating gastrointestinal flora. The metagen hydrogel disclosed by the invention has the effect of effectively relieving gastric ulcer symptoms caused by alcohol, and is suitable for being developed and applied as a medicine or a health-care product for relieving alcoholic gastric ulcer.
Owner:NORTHEAST AGRICULTURAL UNIVERSITY

Application of LGG exosome in preparation of medicine for preventing and treating sepsis acute lung injury

The invention relates to the field of acute lung injury caused by sepsis, in particular to application of lactobacillus rhamnosus exosome in preparation of medicine for treating and / or preventing acute lung injury caused by sepsis of subjects, and the acute lung injury caused by sepsis is acute complication of sepsis. The sepsis is caused by bacterial infection, and the particle size of the lactobacillus rhamnosus exosome ranges from 50 nm to 120 nm. The lactobacillus rhamnosus exosome provided by the invention can prevent and / or timely and effectively prevent the development of the disease course of a subject at the initial stage of sepsis acute lung injury, and finally, the treatment success rate of the subject is increased, and the prognosis of the subject is improved.
Owner:成都市第五人民医院

Application of GABA (gamma-aminobutyric acid) driven by lactobacillus rhamnosus in treatment of cerebral malaria of mice

The invention belongs to the technical field of biomedicine, and particularly relates to application of GABA (gamma-aminobutyric acid) driven by lactobacillus rhamnosus to treatment of cerebral malaria of mice. According to the invention, the obviously enriched lactobacillus muricatum is found, and the lactobacillus muricatum is proved to be capable of generating GABA (gamma-aminobutyric acid). Afterwards, on the mouse cerebral malaria model, under the condition that the lactobacillus rhamnosus and the GABA are independently used or auxiliary dihydroartemisinin is used, the effect of the lactobacillus rhamnosus and the GABA on improving and treating the mouse cerebral malaria is evaluated. Results show that the strain and the metabolite GABA thereof can effectively improve behavioristics of mice and immune pathological injuries of all organs, reduce protozoemia and prolong the lifetime of the mice whether the strain is independently used or combined with dihydroartemisinin, and can effectively treat cerebral malaria of the mice compared with the strain which is independently used with drugs. The invention provides a brand-new solution for treating severe malaria, especially human brain malaria, caused by malignant malaria from the perspective that the probiotics drive metabolites of the probiotics to assist the anti-malarial drug in treating rat brain malaria.
Owner:HUBEI UNIV OF MEDICINE +1

Application of lactobacillus rhamnosus B2-1 from breast milk to preparation of product for relieving specific dermatitis

The invention provides application of lactobacillus rhamnosus B2-1 sourced from breast milk in preparation of products for relieving specific dermatitis, the lactobacillus rhamnosus B2-1 is preserved in China General Microbiological Culture Collection Center (CGMCC) on December 8, 2022, and the preservation number is CGMCC NO.26167. The lactobacillus rhamnosus B2-1 has been preserved in the China General Microbiological Culture Collection Center (CGMCC). The lactobacillus rhamnosus B2-1 disclosed by the invention has a good effect of relieving the specific dermatitis, and has potential functional development potential.
Owner:BEIJING SANYUAN FOOD

Lactobacillus rhamnosus for relieving toxicity of heavy metal cadmium and application of lactobacillus rhamnosus

The invention belongs to the technical field of microorganisms, and discloses lactobacillus rhamnosus capable of relieving toxicity of heavy metal cadmium and application of the lactobacillus rhamnosus. The lactobacillus rhamnosus is preserved in the China Center for Type Microbiological Culture Collection, the preservation address is Wuhan University, Hubei province, and the preservation number is CCTCC No.M20241815. The lactobacillus rhamnosus is named lactobacillus rhamnosus. The lactobacillus rhamnosus provided by the invention is derived from intestinal tracts of healthy stichopus japonicus, has good heavy metal cadmium tolerance and removal capacity, and is expected to be developed and applied to the healthy food industry.
Owner:SHANDONG BUSINESS INST

Lactobacillus rhamnosus strain with antiallergic activity and preparation method thereof

The invention discloses a lactobacillus rhamnosus strain with antiallergic activity and a preparation method thereof, the strain is lactobacillus rhamnosus Lrn-PG-06, the classification name of the strain is Lactobacillus rhamnosus, the preservation number is CGMCC (China General Microbiological Culture Collection Center) No.3077, the preservation time is March 21, 2024, the preservation unit is China General Microbiological Culture Collection Center, the preservation number is CGMCC No.3077, and the preservation number is CGMCC No.3077. The address is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing. The lactobacillus rhamnosus Lrn-PG-06 strain is high in acid resistance, alkali resistance and cholate resistance, high in simulated gastrointestinal fluid resistance and high in oxidation resistance, has the advantage of resisting allergy, and solves the problems that at present, allergic diseases are mainly treated by drugs or are prevented from being in contact with allergens in the environment and food, but due to the fact that the drugs are large in toxic and side effects, the allergens cannot be in contact with the allergens in the environment and food. And allergens causing anaphylaxis are difficult to determine, so that allergic diseases are difficult to treat or prevent.
Owner:HEILONGJIANG UNIV +1

Lactobacillus-sourced extracellular vesicle and application thereof in prevention and treatment of necrotizing enterocolitis

The invention relates to the technical field of biological medicine, in particular to a lactobacillus-sourced extracellular vesicle and application of the lactobacillus-sourced extracellular vesicle in prevention and treatment of necrotizing enterocolitis, the extracellular vesicle is prepared from lactobacillus, the lactobacillus is Lactobacillus rhamnosus GG, the strain is purchased in the American Center for Type Culture Collection, and the preservation number is ATCC 53103. The preparation method of the extracellular vesicles comprises the following steps: carrying out ultracentrifugation on a lactobacillus culture solution, removing thalli, then collecting supernate, carrying out primary microfiltration, taking micro-filtrate, carrying out differential centrifugation, resuspending precipitates by using PBS, then carrying out secondary microfiltration, collecting the micro-filtrate, carrying out density gradient centrifugation, and collecting a 30-45% interface vesicle layer. The invention discloses a synergistic effect mode between intestinal symbiotic flora and intestinal epithelial cell metabolic molecules for the first time, and the discovery is expected to construct a brand-new mechanism normal form for regulating the host intestinal barrier function by flora.
Owner:DONGGUAN EIGHTH PEOPLES HOSPITALDONGGUAN CHILDRENS HOSPITAL

Synbiotic composition with bacteriostatic and anti-inflammatory effects and preparation method thereof

The invention discloses a synbiotics composition with bacteriostatic and anti-inflammatory effects, which comprises probiotics and prebiotics in parts by weight, the probiotics comprise the following components in parts by weight: 0.05 to 0.15 part of freeze-dried powder of lactobacillus rhamnosus PB-LR76, 0.05 to 0.15 part of freeze-dried powder of lactobacillus acidophilus HH-LA26, 0.05 to 0.15 part of freeze-dried powder of lactobacillus bulgaricus HH-LB57, 0.05 to 0.15 part of freeze-dried powder of bifidobacterium lactis HH-BA68, 0.05 to 0.15 part of freeze-dried powder of lactobacillus reuteri PB-LR09, and 0.05 to 0.15 part of freeze-dried powder of lactobacillus plantarum HH-LP56; the prebiotics are fructo-oligosaccharide or a rhizoma polygonati extract. Compared with the single use of probiotics or prebiotics, the synbiotics composition disclosed by the invention has stronger antibacterial and anti-inflammatory effects. The invention further discloses application of the synbiotics composition in preparation of a medicine for treating enteritis.
Owner:TAIAN CENT HOSPITAL (TAIAN CENT HOSPITAL AFFILIATED TO QINGDAO UNIV TAISHAN MEDICAL NURSING CENT)

Plant lactobacillus MG360 capable of improving constipation, compound probiotic fermentation preparation and application of compound probiotic fermentation preparation

The invention provides a lactobacillus plantarum MG360 with the efficacy of improving constipation, the preservation number of the lactobacillus plantarum MG360 is CGMCC NO 32953, and the lactobacillus plantarum MG360 is preserved in China General Microbiological Culture Collection Center on February 14, 2025. Meanwhile, the invention further provides a compound probiotic composition of the plant lactobacillus MG360 and the lactobacillus rhamnosus Eupro, the compound probiotic composition can be used for fermenting the coix seed enzymatic hydrolysate, and a fermentation product of the compound probiotic composition is rich in ferulic acid, vanillic acid, short-chain fatty acid, glutamic acid and the like. The fermentation product can obviously shorten the first black excrement discharge time of constipation mice, obviously improve the small intestine propulsion rate and the excrement water content, obviously improve the level of motility hormone (MTL, Gas, AchE, SP and 5-HT) in serum of the constipation mice and obviously reduce the level of inhibitory hormone (SS and VIP), and it is indicated that the fermentation product can relieve constipation by adjusting the gastrointestinal hormone peptide level. The preparation method of the probiotic preparation containing the plant lactobacillus MG360 and the compound probiotic fermentation preparation of the compound probiotic composition is simple, large-scale production can be achieved, and good application prospects are achieved.
Owner:HUNAN NUTRITION TREE BIOTECHNOLOGY CO LTD

Lactobacillus rhamnosus BN02 for improving joint inflammation and promoting bone health, metagen and application of lactobacillus rhamnosus BN02 and metagen

The invention discloses a lactobacillus rhamnosus capable of improving joint inflammation and promoting bone health, a metagen and application of the lactobacillus rhamnosus, the lactobacillus rhamnosus is lactobacillus rhamnosus BN02, the lactobacillus rhamnosus is preserved in China General Microbiological Culture Collection Center on November 27, 2023, and the preservation number is CGMCC No.29133. The lactobacillus rhamnosus can be used for improving joint inflammation and promoting bone health. The lactobacillus rhamnosus BN02 can reduce the number of gram-negative bacteria in intestinal tracts of arthritis patients, increase the synthesis amount of bone collagen, and is beneficial to promoting absorption of vitamin C by the intestinal tracts, improving joint inflammation and promoting bone health.
Owner:湖南益百益优生物科技有限公司

Lactobacillus rhamnosus capable of enhancing memory ability, fermented food of lactobacillus rhamnosus and application of lactobacillus rhamnosus

The invention discloses a lactobacillus rhamnosus HL8 capable of enhancing memory ability as well as a fermented food and application thereof, and belongs to the technical field of microorganisms. The lactobacillus rhamnosus HL8 can be used for preparing functional food, health care products and medicines for improving individual memory ability or improving memory impairment, the invention further provides fermented food, the fermented food is prepared by fermenting the lactobacillus rhamnosus, and the fermented food comprises solid food, liquid food and semi-solid food. And the method has a very wide application prospect.
Owner:JIANGNAN UNIV

Biological combined preparation for allergic rhinitis and preparation method thereof

The invention provides a biological combined preparation for allergic rhinitis and a preparation method of the biological combined preparation. The preparation comprises antibacterial polysaccharide, a centipeda minima extract, anti-allergic probiotics, an active polypeptide compound, sodium hyaluronate, an immunomodulator, a penetration enhancer, a biological adhesive and the like. Wherein the antibacterial polysaccharide can be selected from various natural polysaccharides; the centipeda minima extract is obtained by a specific ethanol reflux method; the antiallergic probiotics comprise lactobacillus acidophilus, lactobacillus rhamnosus and lactobacillus reuteri; the active polypeptide compound consists of thymosin, glutathione and osteogenic peptide. The preparation method comprises the following steps: sequentially mixing the components, carrying out high-pressure homogenization treatment, carrying out ultrasonic treatment, adding probiotics, stirring, intercepting with an ultrafiltration membrane, freeze-drying and the like. The preparation disclosed by the invention can form a uniform nano-scale particle suspension, so that the release rate and the absorption efficiency of the medicine are further improved, and an efficient, safe and convenient novel method is provided for treating the allergic rhinitis.
Owner:GUANGZHOU GREENWALL BIOMEDICAL TECH CO LTD

Lactobacillus rhamnosus strain, viable bacteria formulation and preparation method therefor and use thereof

PCT designated stage expiredWO2024260442A1BacteriaMetabolism disorderBiotechnologyMicroorganism
The present application relates to the technical field of microorganisms, and in particular to a Lactobacillus rhamnosus strain, a viable bacteria formulation and a preparation method therefor and a use thereof. The preservation number of the Lactobacillus rhamnosus strain is CGMCC No. 25682. The Lactobacillus rhamnosus strain and the viable bacteria formulation thereof have good free radical scavenging, oxidative stress response, anti-oxidation and anti-aging capabilities, have the potential of regulating blood sugar, can adjust the immunity, and are used for maintaining a balance in intestinal flora.
Owner:COREE CO LTD

Lactobacillus rhamnosus HZBX-05 and application thereof

The invention relates to the technical field of microorganisms, in particular to lactobacillus rhamnosus HZBX-05 and application thereof.The lactobacillus rhamnosus HZBX-05 is sent to the China General Microbiological Culture Collection Center on July 27th, 2023 to be preserved in the China General Microbiological Culture Collection Center, the preservation number of the lactobacillus rhamnosus HZBX-05 is CGMCC NO.987, and the preservation number of the lactobacillus rhamnosus HZBX-05 is CGMCC NO.989. The lactobacillus rhamnosus HZBX-05 is CGMCC NO.989. The lactobacillus rhamnosus HZBX-05 is CGMCC NO.989. The preservation number is CGMCC (China General Microbiological Culture Collection Center) NO.28035, and the address is Institute of Microbiology, Chinese Academy of Sciences, No.3, No.1 Yard, West Beichen Road, Chaoyang District, Beijing; the separated Lactobacillus rhamnosus HZBX-05 is continuously treated for 7 hours in a simulated gastric acid cholate environment, and the result shows that the HZBX-05 still has high survival rate, has the capability of being highly adsorbed to intestinal cells Caco-2 cells, has the capability of inhibiting various pathogenic bacteria, has immunoregulation and anti-inflammation effects, has the effect of resisting helicobacter pylori, and can be used for preparing an anti-inflammatory drug. The symptoms of female vaginitis can be improved.
Owner:HANGZHOU TARGETED FOOD TECH CO LTD

Preparation method of high-stability beta-glucan yoghourt

The invention discloses a preparation method of high-stability beta-glucan yoghourt. Mixing the sterilized fresh milk with a composite strain consisting of lactobacillus delbrueckii subsp. Bulgaricus, streptococcus salivarius subsp. Thermophilus, bifidobacterium animalis subsp. Lactis, plant lactobacillus, bifidobacterium breve, lactobacillus paracasei, lactobacillus helveticus, lactobacillus rhamnosus and bifidobacterium longum subsp. Longum, and fermenting; and adding beta-glucan into the fermented yoghourt to obtain the high-stability beta-glucan yoghourt. Before beta-glucan is added, the compound bacterial strain is added into the milk, protein in the milk can be gathered under the action of the compound bacterial strain to form a three-dimensional curd network, so that the flowability of a system is reduced, then glucan is added, and the glucan can be uniformly dispersed in curd gaps, so that the glucan is prevented from being excessively combined with the protein in the milk; the stability of a yoghourt system is improved.
Owner:FUTURE FOOD (BAI MA) RESEARCH INSTITUTE +1